Brief: SynAct Pharma Initiates RESOVIR Scientific And Clinical Collaboration To Explore Ap1189 In Viral Infections

SynAct Pharma AB

28/08/2020 08:27

Aug 28 (Reuters) - SynAct Pharma AB  SYNACT.TE :
    * SYNACT PHARMA INITIATES RESOVIR: SCIENTIFIC AND CLINICAL
COLLABORATION TO EXPLORE AP1189 IN VIRAL INFECTIONS
    * FIRST STEP OF COLLABORATION WILL BE TO RUN AN EXPLORATORY
CLINICAL STUDY IN COVID-19 INFECTED PATIENTS AIMED TO
INVESTIGATE REPEATED DOSING OF SYNACT PHARMA'S CLINICAL STAGE
COMPOUND AP1189
    * LATER COLLABORATION WILL INVESTIGATE POTENTIAL OF
PROMOTING
INFLAMMATORY RESOLUTION IN OTHER VIRAL DISEASES SUCH AS DENGUE
AND INFLUENZA VIRUS

Source text for Eikon:  ID:nWkr7qCd19 
Further company coverage:  SYNACT.TE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))